Universal Registration Document Including The Annual Financial Report

Overview

The report describes the company's 2023 clinical-stage focus on temelimab, including recruitment of 203 patients for the GNC-501 Post-COVID Phase 2 trial, with results expected by June 2024. It reports a consolidated net loss of (14,757.0) thousand EUR for 2023 and no revenue. The Group employed 19 people at year-end, while the document provides extensive clinical, financial, governance, and regulatory disclosures.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Publication date: 30 April 2024
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services